<DOC>
	<DOC>NCT00497679</DOC>
	<brief_summary>The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies.</brief_summary>
	<brief_title>AZD1152 in Patients With Advanced Solid Malignancies-Study 3</brief_title>
	<detailed_description />
	<criteria>Histological or cytological confirmation of a solid, malignant tumour Participation in an investigational drug study within 21 days prior to entry or who have not recovered from the effects of an investigational study drug Treatment with radiotherapy/chemotherapy with 4 weeks of first dose Recent major surgery within 4 weeks prior to entry to the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>advanced solid tumours</keyword>
</DOC>